Surrozen (NASDAQ: SRZN) has announced its Investigational New Drug (IND) application for SZN-8141 for the treatment of diabetic macular edema (DME) has become effective, enabling advancement to clinical development.
SZN-8141 is a bifunctional Wnt agonist and vascular endothelial growth factor antagonist antibody being developed as an intravitreal injection for the treatment of DME. Surrozen expects to dose the first patient in DUET, a Phase 1b/2a clinical study evaluating SZN-8141 in patients with DME, in the fourth quarter of 2026.
In a statement, Craig Parker, CEO of Surrozen, commented, “FDA clearance of the SZN-8141 IND marks an important milestone for Surrozen as we advance our Wnt-based ophthalmology pipeline into clinical development. We look forward to initiating the DUET study and evaluating SZN-8141 in patients with diabetic macular edema. Importantly, this milestone also satisfies the condition for the second closing of our March 2025 private placement, which is expected to provide approximately $95.1 million in gross proceeds to support the advancement of SZN-8141 and SZN-8143.”
